Caribou Biosciences: Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited natural killer (NK) cell therapies, and engineered gut microbes.

Investors include: Anterra Capital; Dupont; F-Prime Capital; Genoa Ventures; Genus; Heritage Group; Maverick Ventures; Mission Bay Capital; Novartis